BF2.649

Phase 3Small molecule

BBioprojet

BF2.649 is one of 75 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

NarcolepsyActive, not recruiting

CataplexyActive, not recruiting

Obstructive Sleep ApneaPhase 2

Active, not recruiting

NarcolepsyPhase 3

Active, not recruiting

CataplexyPhase 3

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Obstructive Sleep Apnea

#DrugCompanyPhaseTrials

Asmanex

Novartis

Phase 3

1 2

Mounjaro

Eli Lilly

Phase 3

1 3

Farxiga

AstraZeneca

Phase 3

1 4

Foundayo

Eli Lilly

Phase 3

1 5

MS Contin

Lunesta

3 7

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

2 8

Ketalar

AAultman Health Foundation

Phase 3

2 9

Imovane

TTaisho Pharmaceutical Co., Ltd.

Phase 3

1 10

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Narcolepsy3 trials

Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy

Completed·BBioprojet·Phase 3·NCT01067222·110 enrolled

Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)

Completed·BBioprojet·Phase 3·NCT01399606·102 enrolled

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

Completed·BBioprojet·Phase 3·NCT01638403·180 enrolled

AIN2 trials

BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.

Completed·BBioprojet·Phase 3·NCT01072968·268 enrolled

BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS

Completed·BBioprojet·Phase 3·NCT01071876·244 enrolled

Excessive Daytime Sleepiness2 trials

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

Completed·BBioprojet·Phase 3·NCT01066442·273 enrolled

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

Completed·BBioprojet·Phase 3·NCT01036139·268 enrolled

Cataplexy1 trial

Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy

Completed·BBioprojet·Phase 3·NCT01067235·14 enrolled

Renal Impairment1 trial

Pharmacokinetics of BF2.649 in Renal Impairment

Completed·BBioprojet·Phase 1·NCT01619033·25 enrolled

3 more indications

Obstructive Sleep Apnea1 trial

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

Completed·BBioprojet·Phase 2·NCT01620554·110 enrolled

TED1 trial

Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)

Completed·BBioprojet·Phase 3·NCT01789398·51 enrolled

Unspecified1 trial

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT00690274·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for BF2.649. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BF2.649 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BF2.649. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioprojet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBioprojet

BF2.649

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Narcolepsy3 trials

AIN2 trials

Excessive Daytime Sleepiness2 trials

Cataplexy1 trial

Renal Impairment1 trial

Obstructive Sleep Apnea1 trial

TED1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News